Samarium-153 DOTMP - IGL Pharma
Alternative Names: 153-Sm-DOTMP; CycloSam; Sm-153-DOTMP; TLX-090; TLX090-TxLatest Information Update: 03 Nov 2025
At a glance
- Originator IsoTherapeutics
- Developer IsoTherapeutics; Telix Pharmaceuticals
- Class Antineoplastics; Radiopharmaceuticals; Small molecules
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Yes - Osteosarcoma
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Bone metastases
- Discontinued Osteosarcoma
Most Recent Events
- 23 Oct 2025 Phase-I clinical trials in Bone metastases (IV) (NCT07197645)
- 29 Aug 2025 Discontinued - Preclinical for Osteosarcoma in USA (Parenteral) (Telix Pharmaceuticals pipeline, August 2025)
- 28 May 2025 No recent reports of development identified for phase-I development in Bone metastases(In adolescents, In the elderly, In adults) in USA (Parenteral)